HCPLive

Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD

Oct 5, 2026 · 0:05:33

Listen to Episode

✨ AI Summary

Ritlecitinib stabilizes vitiligo, offering meaningful outcomes.
Phase 3 Tranquillo trial results presented at EADV Congress.
Stabilizing vitiligo is a key benefit of ritlecitinib treatment.

Guests on This Episode

Iltefat Hamzavi

researcher · 5 podcast appearances

More from HCPLive

Subcutaneous Furosemide Bioequivalent to IV, Bioavailable Across Multiple Injection Sites

Oct 12, 2026 · 0:03:18

Targeting Senescent Cells in Actinic Keratosis With RLS-1496

Oct 12, 2026 · 0:04:25

Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD

Oct 12, 2026 · 0:03:33

Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF

Oct 12, 2026 · 0:06:00

View all episodes →